Genfit S.A. (EPA:GNFT – Get Free Report)’s stock price traded up 0.7% during mid-day trading on Thursday . The company traded as high as €3.50 ($3.57) and last traded at €3.50 ($3.57). 145,395 shares traded hands during mid-day trading, The stock had previously closed at €3.47 ($3.54).
Genfit Stock Down 1.9 %
The stock’s fifty day moving average is €3.96 and its 200-day moving average is €4.17.
Genfit Company Profile
Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Featured Articles
- Five stocks we like better than Genfit
- 3 Fintech Stocks With Good 2021 Prospects
- 3 Defense Stocks Gaining From Budget and Interest Rate Pressures
- How to Invest in Small Cap Stocks
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- Mastering Discipline: Overcoming Emotional Challenges In Trading
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.
